Articoli correlati

Zilurgisertib (Atebrioz)

Approved F.O.P. therapy marketed as Atebrioz; inhibits the ALK2 protein involved in directing bone growth.

• Nuovi trattamenti offrono speranza ai pazienti con il disturbo osseo incontrollato F.O.P.